Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib plus FOLFOX vs bevacizumab plus FOLFOX in first-line metastatic colorectal cancer
2007-002987-84Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sunitinib in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Apr 2008; status: terminated.
02
Drugs
sunitinib
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2007-002987-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002987-84.